Fadi W. Abdul-Karim

Fadi W. Abdul-Karim

Auto-generated profile, based on publicly available information

Fadi W. Abdul-Karim

Anatomic Pathology, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1990 in Histopathology
Verified
Journal Article
Closed access
PDF file
MWM.G. Weaver
M.G. Weaver
FAF.W. Abdul‐Karim
F.W. Abdul‐Karim

4 December 2023 in Advances in Anatomic Pathology
Verified
Journal Article
Closed access
CSCasey P. Do Schukow
Casey P. Do Schukow
LPLavisha S. Mbbs Punjabi
Lavisha S. Mbbs Punjabi
FAFadi W. Md Abdul-Karim
Fadi W. Md Abdul-Karim
#PathTwitter is a well-known virtual community that has historically been positive for pathologists, trainees, and medical students worldwide to communicate, collaborate, and connect for free. However, in 2023, the popular social media platform Twitter (parent company: X Corp.) transitioned to “X” and, with this, #PathTwitter evolved into #PathX. Although the overall user experience of X and Twitter has not changed significantly, this transition brought much anecdotal hesitancy from the online virtual pathology community early on. Thus, the purpose of this review is to discuss the background of Twitter’s importance in pathology, the implications of this transition to the online pathology community, current views from this community regarding Twitter versus X, and to provide an overview of pertinent changes in the platform, as well as of different popular social media platforms that may be used by pathologists in 2024.

25 January 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LALindsey J. Anstine
Lindsey J. Anstine
PMParth R. Majmudar
Parth R. Majmudar
AAAmy Aponte
Amy Aponte
Salendra SinghSalendra Singh
Salendra Singh
RZRan Zhao
Ran Zhao
RKRuth Keri
Ruth Keri
Breast cancer subtypes and their phenotypes parallel different stages of the mammary epithelial cell developmental hierarchy. Discovering mechanisms that control lineage identity could provide novel avenues for mitigating disease progression. Here we report that the transcriptional corepressor TLE3 is a guardian of luminal cell fate in breast cancer and operates independently of the estrogen receptor. In luminal breast cancer, TLE3 actively repressed the gene-expression signature associated with highly aggressive basal-like breast cancers (BLBC). Moreover, maintenance of the luminal lineage depended on the appropriate localization of TLE3 to its transcriptional targets, a process mediated by interactions with FOXA1. By repressing genes that drive BLBC phenotypes, including SOX9 and TGFβ2, TLE3 prevented the acquisition of a hybrid epithelial–mesenchymal state and reduced metastatic capacity and aggressive cellular behaviors. These results establish TLE3 as an essential transcriptional repressor that sustains the more differentiated and less metastatic nature of luminal breast cancers. Approaches to induce TLE3 expression could promote the acquisition of less aggressive, more treatable disease states to extend patient survival. Significance: Transcriptional corepressor TLE3 actively suppresses SOX9 and TGFβ transcriptional programs to sustain the luminal lineage identity of breast cancer cells and to inhibit metastatic progression.

1 June 1997 in Journal of Urology
Verified
Journal Article
Closed access
LMLee Anne Matthews
Lee Anne Matthews
FAFadi W. Abdul-Karim
Fadi W. Abdul-Karim
JEJack S. Elder
Jack S. Elder
We attempted to determine whether preoperative human chorionic gonadotropin (HCG) improves fertility in intra-abdominal rat testes subjected to orchiopexy. Newborn male Sprague-Dawley rats were made cryptorchid by bilateral gubernaculum excision at age 14 days. Select rats served as controls and underwent sham operations. Half of the animals were injected with 10 international units HCG daily from days 14 to 28. On day 28 the animals were divided into group 1-6 that underwent sham operation with or without HCG, group 2-6 with cryptorchidism with or without HCG, group 3-22 that underwent standard orchiopexy with or without HCG and group 4-22 that underwent Fowler-Stephens orchiopexy with or without HCG. Contralateral orchiectomy was performed simultaneously. On day 65 each male rat was mated with 2 female rats for 3 ovulatory cycles. Mean testicular weight was markedly decreased in cryptorchid compared to sham operated testes (87.2 versus 344 mg./100 gm. body weight). Mean testicular weight was similar after standard and Fowler-Stephens orchiopexy. HCG enhanced mean testicular weight after sham operation, standard orchiopexy and Fowler-Stephens orchiopexy (403 versus 344, 193 versus 176 and 194 versus 175 mg./100 gm. body weight, respectively) but these differences were not statistically significant. Fertility was present in all 6 sham operated, 0 of the 6 cryptorchid, 1 of the 11 standard orchiopexy and 1 of the 8 Fowler-Stephens orchiopexy rats. Of the HCG treated animals 2 of the 8 that underwent Fowler-Stephens orchiopexy and 1 of the 8 that underwent standard orchiopexy were fertile. Mean weight of the testes associated with pregnancy was significantly greater than those not associated with pregnancy (p < 0.001). The intra-abdominal rat testis has limited fertility potential after orchiopexy that is not improved with preoperative HCG. After orchiopexy fertility correlates closely with testicular weight.

15 January 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
LCLeslie Cuellar-Vite
Leslie Cuellar-Vite
EDElyse M. Donaubauer
Elyse M. Donaubauer
KWKristen L. Weber-Bonk
Kristen L. Weber-Bonk
JBJessica R. Bobbitt
Jessica R. Bobbitt
NINatasha N. Ingles
Natasha N. Ingles
RKRuth Keri
Ruth Keri
EGFR is a highly expressed driver of many cancers, yet the utility of EGFR inhibitors (EGFRi) is limited to cancers that harbor sensitizing mutations in the EGFR gene because of dose-limiting toxicities. Rather than conventionally blocking the kinase activity of EGFR, we sought to reduce its transcription as an alternative approach to broaden the therapeutic window for EGFR inhibitors targeting wild-type (WT) or mutant EGFR. We found that YES1 is highly expressed in triple-negative breast cancer (TNBC) and drives cell growth by elevating EGFR levels. Mechanistically, YES1 stimulates EGFR expression by signaling to JNK and stabilizing the AP-1 transcription factor c-Jun. This effect extends beyond TNBC as YES1 also sustains EGFR expression in non–small cell lung cancer cells, including those that harbor the EGFR gatekeeper mutation T790M. The novel ability of YES1 to regulate the expression of WT and mutant EGFR mRNA and protein provides a potential therapeutic opportunity of utilizing YES1 blockade to broadly increase the efficacy of EGFR inhibitors. Indeed, we observed synergy within in vitro and in vivo models of TNBC and non–small cell lung cancer, even in the absence of EGFR-activating mutations. Together, these data provide a rationale for blocking YES1 activity as an approach for improving the efficacy of EGFR-targeting drugs in cancers that have generally been refractory to such inhibitors. Implications: YES1 sustains EGFR expression, revealing a therapeutic vulnerability for increasing the efficacy of EGFR inhibitors by lowering the threshold for efficacy in tumors driven by the WT or mutant receptor.

4 April 2023
Verified
Other
Open access
LALindsey J. Anstine
Lindsey J. Anstine
PMParth R. Majmudar
Parth R. Majmudar
AAAmy Aponte
Amy Aponte
Salendra SinghSalendra Singh
Salendra Singh
RZRan Zhao
Ran Zhao
RKRuth Keri
Ruth Keri